ViGenCell Inc.
Research ViGenCell Inc. (308080.KQ) on Bullrun: market cap KRW 111.52B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker308080.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 111.52B
- Financial periodQ2 2026
- RevenueKRW 571.22M
- Net income-KRW 2.34B
- Free cash flow-KRW 1.89B
- Gross margin3.2%
Valuation Snapshot
latest market cap is KRW 111.52B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 111.52B | n/a | n/a | n/a |
Dividend history
About ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ViGenCell Inc.'s market cap?
ViGenCell Inc.'s market capitalization is KRW 111.52B.
What does ViGenCell Inc. do?
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.